New York, May 21, 2026, 12:07 EDT
- Lakeside Holding was recently trading down 10.6% at $0.514, close to its session low. That puts the company’s market value near $17.7 million.
- March-quarter numbers are in: revenue was $1.33 million, net income $142,408. That compares to $497,276 in revenue and a $1.07 million net loss for the same quarter last year.
- The stock is still trading under Nasdaq’s $1 minimum, and the company faces a compliance deadline on July 7.
Lakeside Holding Limited stock dropped hard Thursday. The small-cap firm said it turned a quarterly profit, but the market focused on lingering losses, an ongoing reset of its business, and a looming deadline to keep its Nasdaq listing.
LSH dropped 10.6% to $0.514 after swinging from $0.514 to $0.579. The fall outpaced the Nasdaq Composite’s 0.38% midday slide.
Lakeside’s latest filing gives a first look at the company since dropping its ABL Chicago freight unit and turning to pharma distribution in China. The company said ongoing business is now centered on pharma products through Hupan Pharmaceutical, with revenue mostly coming from infusion products, specialty prescription drugs, and medical nutrition.
Lakeside marked ABL Chicago as a discontinued operation, logging a $2.56 million gain related to leaving that business. Without that one-time boost, the ongoing business reported an operating loss of $1.58 million for the March quarter.
Revenue jumped 167% to $1.33 million in the quarter ended March 31, up from $497,276 a year ago. Net income hit $142,408, swinging from a $1.07 million loss, with discontinued operations boosting results.
Lakeside reported gains from pharmaceutical distribution. The company said revenue in the segment increased as infusion-product sales picked up, and it ended the quarter with 12 active customers, up from four. Gross margin slipped to 73.8% from 76.0% on lower supplier purchase rebates, according to Lakeside.
Pharmaceutical distribution revenue jumped 614.1% to $5.11 million for the nine-month stretch. Infusion products made up around 93% of that slice. Active customers climbed to 14, up from eight.
Lakeside started shifting in late 2024. Chairman and CEO Henry Liu called the Hupan buy an “important foothold” in medical logistics when the deal was first announced. The latest filing shows medical logistics is now basically the operating core. PR Newswire
Competitive moves were mixed, but not as soft. Expeditors International dropped 1.4%. C.H. Robinson slid 2.5%. Freightos eased 1.0%. All saw smaller losses than LSH’s fall.
The Nasdaq listing problem is still weighing on Lakeside. Nasdaq told Lakeside on Jan. 7 it was under the $1 minimum bid price needed to keep its spot on the Nasdaq Capital Market. The company has until July 7 to fix it, usually by getting the stock to close at $1 or more for 10 straight business days.
The filing flagged bigger risks. Lakeside said there is “substantial doubt” about whether it can stay in business — meaning its ability to fund daily operations or pay its bills is in question. The company pointed to an $8.1 million accumulated deficit, a $3.5 million loss from continuing operations over nine months, and $3.0 million in cash used by continuing operations. SEC
Liquidity is in focus. Lakeside had $1.3 million in cash at March 31. The company said a loan receivable of about $8.7 million from an unrelated third party made up 49% of its current assets. A major default or payment delay on that loan could squeeze near-term liquidity and leave Lakeside looking for other funding.
U.S. stocks slid on Thursday, with oil and Treasury yields up. AP said the S&P 500, Dow, and Nasdaq were all down late in the morning. Lakeside faces a different set of hurdles. The company now has to show its China pharma unit can turn an operating profit, recover its loan receivable, and push the share price above Nasdaq’s required level.
